Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $20.80.

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. BTIG Research started coverage on Jade Biosciences in a research report on Thursday, October 9th. They issued a “buy” rating and a $28.00 target price on the stock. Guggenheim upped their price target on Jade Biosciences from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. HC Wainwright initiated coverage on Jade Biosciences in a research note on Wednesday, January 7th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Wall Street Zen raised Jade Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th.

Jade Biosciences Stock Down 4.2%

NASDAQ:JBIO opened at $16.31 on Friday. Jade Biosciences has a 52 week low of $6.57 and a 52 week high of $100.10. The stock’s fifty day moving average is $14.26 and its two-hundred day moving average is $10.52. The company has a market capitalization of $804.25 million, a P/E ratio of -1.46 and a beta of 1.02.

Jade Biosciences (NASDAQ:JBIO) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc acquired a new position in shares of Jade Biosciences in the second quarter valued at approximately $29,000. Russell Investments Group Ltd. purchased a new position in Jade Biosciences in the 2nd quarter valued at approximately $31,000. BNP Paribas Financial Markets acquired a new position in shares of Jade Biosciences in the second quarter worth $32,000. Ameritas Investment Partners Inc. acquired a new position in shares of Jade Biosciences in the second quarter worth $33,000. Finally, New York State Common Retirement Fund increased its position in shares of Jade Biosciences by 4,180.3% during the third quarter. New York State Common Retirement Fund now owns 5,222 shares of the company’s stock worth $45,000 after acquiring an additional 5,100 shares during the period.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.